Impacto del tiempo de intervención en pacientes con IAMSEST: diseño del estudio IMPACT-TIMING-GO

  1. Felipe Díez del Hoyo 1
  2. P. Díez Villanueva 2
  3. María Thiscal López Lluva 3
  4. María Abellás 4
  5. Ignacio Amat Santos 5
  6. Pablo Bazal Chacón 6
  7. Anna Carrasquer 7
  8. Miguel Corbí Pascual 8
  9. David Escribano Alarcón 9
  10. Ane Elorriaga Madariaga 10
  11. Sergio García Blas 11
  12. Teresa Giralt Borrell 12
  13. Alfonso Jurado Román 13
  14. Joan Isaac Llaó Ferrando 14
  15. Lucía Matute Blanco 15
  16. Martín Negreira Caamaño 16
  17. Lucía Pérez Cebey 17
  18. Ricardo Rivera López 18
  19. Carolina Robles 19
  20. Pablo Salinas Sanguino 20
  21. Fernando Torres Mezcúa 21
  22. Iván Olavarri Miguel 22
  23. Jessica Vaquero Luna 23
  24. Pedro L. Cepas Guillén 24
  1. 1 Servicio de Cardiología, Hospital Gregorio Marañón, Madrid, España
  2. 2 Servicio de Cardiología, Hospital Universitario de La Princesa, Madrid, España
  3. 3 Servicio de Cardiología, Hospital Universitario de León, León, España
  4. 4 Servicio de Cardiología, Hospital Ramón y Cajal, Madrid, España
  5. 5 Servicio de Cardiología, Hospital Clínico Universitario de Valladolid, Valladolid, España
  6. 6 Servicio de Cardiología, Complejo Hospitalario de Navarra, Pamplona, Navarra, España
  7. 7 Servicio de Cardiología, Hospital Joan XXIII, Tarragona, España
  8. 8 Servicio de Cardiología, Hospital Universitario de Albacete, Albacete, España
  9. 9 Servicio de Cardiología, Hospital Universitario San Juan de Alicante, San Juan de Alicante, Alicante, España
  10. 10 Servicio de Cardiología, Hospital Universitario de Basurto, Bilbao, Vizcaya, España
  11. 11 Servicio de Cardiología, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, España
  12. 12 Servicio de Cardiología, Hospital del Mar, Barcelona, España
  13. 13 Servicio de Cardiología, Hospital La Paz, Madrid, España
  14. 14 Servicio de Cardiología, Hospital de Bellvitge, L’Hospitalet de Llobregat, Barcelona, España
  15. 15 Servicio de Cardiología, Hospital Universitario Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, España
  16. 16 Servicio de Cardiología, Hospital General Universitario de Ciudad Real, Ciudad Real, España
  17. 17 Servicio de Cardiología, Hospital Universitario de A Coruña, A Coruña, España
  18. 18 Servicio de Cardiología, Hospital Virgen de las Nieves, Granada, España
  19. 19 Servicio de Cardiología, Hospital Universitario de Toledo, Toledo, España
  20. 20 Servicio de Cardiología, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, España
  21. 21 Servicio de Cardiología, Hospital Universitario de Alicante Doctor Balmis, Alicante, España
  22. 22 Servicio de Cardiología, Hospital Marqués de Valdecilla, IDIVAL, Santander, Cantabria, España
  23. 23 Servicio de Cardiología, Hospital Txagorritxu, Vitoria, España
  24. 24 Servicio de Cardiología, Hospital Clínic, Barcelona, España
Show affiliations +
Journal:
REC: Interventional Cardiology

ISSN: 2604-7276,  2604-7306

Year of publication: 2023

Volume: 5

Issue: 1

Pages: 14-19

Type: Article

DOI: 10.24875/RECIC.M22000335 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

More publications in: REC: Interventional Cardiology

Abstract

Introduction and objectives: The optimal time to perform a diagnostic coronary angiography in patients admitted due to non-ST-segment elevation acute coronary syndrome (NSTEACS) and start pretreatment with dual antiplatelet therapy is controversial. Our study aims to identify the current diagnostic and therapeutic approach, and clinical progression of patients with NSTEACS in our country. Methods: The IMPACT-TIMING-GO trial (Impact of time of intervention in patients with myocardial infarction with non-ST segment elevation. Management and outcomes) is a national, observational, prospective, and multicenter registry that will include consecutive patients from 24 Spanish centers with a clinical diagnosis of NSTEACS treated with diagnostic coronary angiography and with present unstable or causal atherosclerotic coronary artery disease. The study primary endpoint is to assess the level of compliance to clinical practice guidelines in patients admitted due to NSTEACS undergoing coronary angiography in Spain, describe the use of antithrombotic treatment prior to cardiac catheterization, and register the time elapsed until it is performed. Major adverse cardiovascular events will also be described like all-cause mortality, non-fatal myocardial infarction and non-fatal stroke, and the rate of major bleeding according to the BARC (Bleeding Academic Research Consortium) scale at 1- and 3-year follow-up. Results: This study will provide more information on the impact of different early management strategies in patients admitted with NSTEACS in Spain, and the degree of implementation of current recommendations into the routine clinical practice. It will also provide information on these patients’ baseline and clinical characteristics. Conclusions: This is the first prospective study conducted in Spain that will be reporting on the early therapeutic strategies—both pharmacological and interventional—implemented in our country in patients with NSTEACS after the publication of the 2020 European guidelines, and on the clinical short- and long-term outcomes of these patients.

Bibliographic References

  • 1. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289-1367.
  • 2. Díez-Villanueva P, Méndez CJ, Alfonso F. Non-ST elevation acute coronary syndrome in the elderly. J Geriatr Cardiol JGC. 2020;17:9-15.
  • 3. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:2354-2394.
  • 4. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315.
  • 5. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736-2747.
  • 6. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Rev Esp Cardiol. 2022;75:429.
  • 7. Garcia-Garcia HM, McFadden EP, Farb A, et al. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation. 2018;137:2635-2650.
  • 8. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-3726.
  • 9. Kofoed KF, Kelbæk H, Hansen PR, et al. Early Versus Standard Care Invasive Examination and Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Circulation. 2018;138:2741-2750.
  • 10. Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360:2165-2175.
  • 11. Thiele H, Rach J, Klein N, et al. Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: the Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in NSTEMI (LIPSIA-NSTEMI Trial). Eur Heart J. 2012;33:2035-2043.
  • 12. Milosevic A, Vasiljevic-Pokrajcic Z, Milasinovic D, et al. Immediate Versus Delayed Invasive Intervention for Non-STEMI Patients: The RIDDLE-NSTEMI Study. JACC Cardiovasc Interv. 2016;9:541-549.
  • 13. Montalescot G, Cayla G, Collet JP, et al. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. JAMA. 2009;302: 947-954.
  • 14. Lemesle G, Laine M, Pankert M, et al. Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment: The EARLY Randomized Trial. JACC Cardiovasc Interv. 2020;13:907-917.
  • 15. Janssens GN, van der Hoeven NW, Lemkes JS, et al. 1-Year Outcomes of Delayed Versus Immediate Intervention in Patients With Transient ST-Segment Elevation Myocardial Infarction. JACC Cardiovasc Interv. 2019;12:2272-2282.
  • 16. Ferreira-González I, Permanyer-Miralda G, Marrugat J, et al. MASCARA (Manejo del Síndrome Coronario Agudo. Registro Actualizado) study. General findings. Rev Esp Cardiol. 2008;61:803-816.
  • 17. Barrabés JA, Bardají A, Jiménez-Candil J, et al. Prognosis and management of acute coronary syndrome in Spain in 2012: the DIOCLES study. Rev Esp Cardiol. 2015;68:98-106.
  • 18. Álvarez Álvarez B, Abou Jokh Casas C, Cordero A, et al. Early revascularization and long-term mortality in high-risk patients with non-ST-elevation myocardial infarction. The CARDIOCHUS-HUSJ registry. Rev Esp Cardiol. 2020;73:35-42.
  • 19. Dawson LP, Chen D, Dagan M, et al. Assessment of Pretreatment With Oral P2Y12 Inhibitors and Cardiovascular and Bleeding Outcomes in Patients With Non-ST Elevation Acute Coronary Syndromes: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021;4:e2134322.
  • 20. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369:999-1010.
  • 21. Schüpke S, Neumann FJ, Menichelli M, et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019;381:1524-1534.
  • 22. Tarantini G, Mojoli M, Varbella F, et al. Timing of Oral P2Y12 Inhibitor Administration in Non-ST Elevation Acute Coronary Syndrome. J Am Coll Cardiol. 2020;76:2450-2459.
  • 23. Romaguera R, Ojeda S, Cruz-González I, collaborators of the ACI-SEC, REGISTRY COLLABORATORS. Spanish Cardiac Catheterization and Coronary Intervention Registry. 30th Official Report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2020) in the year of the COVID-19 pandemic. Rev Esp Cardiol. 2021;74:1095-1105.
Data source: Dialnet